Selvita, Orion To Jointly Develop, Commercialise SEL103
As per the contract, Selvita is expected to take up responsibility for early research on the program and for the discovery and early preclinical development of small molecules,
Ultragenyx Pharmaceutical has received accelerated approval from the US Food and Drug Administration (FDA) for its gene therapy, Genglycos (pariglasgene brecaparvovec-opnr), to treat glycogen storage disease type Ia (GSDIa).